Clinical Trial Update: A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE). [Phase 1, Phase 2]

View source ↗

Summary

Eupraxia Pharmaceuticals is recruiting adults with eosinophilic esophagitis for a Phase 1/2 trial of EP-104GI (NCT05608681).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Eosinophilic Esophagitis

Drugs mentioned

• EP-104GI

Snippet

Sponsor: Eupraxia Pharmaceuticals Inc. | Conditions: Eosinophilic Esophagitis | Phase 1, Phase 2 | Status: RECRUITING